Previously we reported that a hexon-modified adenovirus (Ad) vector containing the invasive neutralizing epitope of ( trypomastigote gp83 (Ad5-gp83) provided immunoprotection against infection. The purpose of this work was to design an improved vaccine for using a novel epitope capsid incorporation strategy. Thus， we evaluated the immunoprotection raised by co-immunization with Ad5-gp83 and an Ad vector containing an epitope (ASP-M) of the amastigote surface protein 2.
Previously we reported that a hexon-modified adenovirus (Ad) vector containing the invasive neutralizing epitope of ( trypomastigote gp83 (Ad5-gp83) provided immunoprotection against infection. The purpose of this work was to design an improved vaccine for using a novel epitope capsid incorporation strategy. Thus， we evaluated the immunoprotection raised by co-immunization with Ad5-gp83 and an Ad vector containing an epitope (ASP-M) of the amastigote surface protein 2.
